Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation

Fangmann, JosefJosefFangmannArns, WolfgangWolfgangArnsMarti, Hans-PeterHans-PeterMartiHauss, JohannJohannHaussKetteler, MarkusMarkusKettelerBeckurts, TobiasTobiasBeckurtsBoesmueller, ClaudiaClaudiaBoesmuellerPohanka, ErichErichPohankaMartin, Pierre-YvesPierre-YvesMartinGerhardt, MoritzMoritzGerhardtFarese, StefanStefanFareseNeumayer, Hans-HHans-HNeumayerFloege, JuergenJuergenFloegeGurr, CarolineCarolineGurrBudde, KlemensKlemensBuddeDACH Study Group2024-10-102024-10-102010https://boris-portal.unibe.ch/handle/20.500.12422/72511Early and long-term use of cyclosporine A (CsA) leads to increased risks of renal toxicity. We hypothesized that administration of daclizumab in combination with mycophenolate mofetil (MMF) allows a relevant reduction in the dose of CsA.enImpact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantationarticle10.7892/boris.17961977341700027311310004710.1093/ndt/gfp468